JAMA Surg. 2014 Apr;149(4):356-63. doi: 10.1001/jamasurg.2013.4146.
Central pancreatectomy, as an alternative to standard resection for benign and low-grade pancreatic neoplasms, has been described in mainly small retrospective series.
To describe a large single-center experience with central pancreatectomy.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective case series in a tertiary referral center included 100 consecutive patients undergoing central pancreatectomy with pancreaticogastrostomy from January 1, 2000, to March 1, 2012.
Surgical indications, postoperative morbidity, mortality, and long-term outcomes regarding pancreatic function and recurrence.
Central pancreatectomies were performed mainly for neuroendocrine tumors (35%), intraductal papillary mucinous neoplasms (33%), solid pseudopapillary neoplasms(12%), and mucinous cystadenomas (6%). The postoperative mortality rate was 3% (due to pulmonary embolisms in 2 patients and hemorrhage after pancreatic fistula in 1 patient). Clavien-Dindo III or IV complications occurred in 15%of patients and were due mainly to pancreatic fistula, requiring 10 radiologic drainage procedures, 7 endoscopic procedures, and 6 reoperations overall. After a median follow-up of 36 months, the rates of new-onset exocrine and endocrine insufficiency were 6%and 2%, respectively. Overall, 7 lesions could be considered undertreated, including 3 node-negative R0 microinvasive intraductal papillary mucinous neoplasms (without recurrence at 27, 29, and 34 months) and 4 node-positive neuroendocrine tumors (with 1 hepatic recurrence at 66 months). Among the 25 patients with a doubtful preoperative diagnosis, 9 could be considered over treated (ie, operated on for benign non evolutive asymptomatic lesions).
Central pancreatectomy is associated with an excellent pancreatic function at the expense of a significant morbidity and a non-nil mortality rate,underestimated by the published literature. The procedure is best indicated for benign or low-grade lesions in young and fit patients who can sustain a significant postoperative morbidity and could benefit from the excellent long-term results.
对于良性和低级别胰腺肿瘤,与标准切除术相比,中央胰腺切除术已在主要的小回顾性系列中进行了描述。
描述一个大型单中心的中央胰腺切除术经验。
设计、地点和参与者:一项回顾性病例系列研究,在一家三级转诊中心,包括 2000 年 1 月 1 日至 2012 年 3 月 1 日期间接受胰腺胃吻合术的 100 例连续接受中央胰腺切除术的患者。
手术指征、术后发病率、死亡率以及关于胰腺功能和复发的长期结果。
中央胰腺切除术主要用于神经内分泌肿瘤(35%)、导管内乳头状黏液性肿瘤(33%)、实性假乳头状肿瘤(12%)和黏液性囊腺瘤(6%)。术后死亡率为 3%(由于 2 例肺栓塞和 1 例胰瘘后出血)。15%的患者发生 Clavien-Dindo III 或 IV 级并发症,主要是由于胰腺瘘,需要 10 次放射学引流,7 次内镜检查和 6 次再次手术。在中位随访 36 个月后,新发外分泌和内分泌功能不全的发生率分别为 6%和 2%。总的来说,有 7 个病变可以认为治疗不足,包括 3 个无局部淋巴结转移的 RO 微侵袭性导管内乳头状黏液性肿瘤(分别在 27、29 和 34 个月无复发)和 4 个有局部淋巴结转移的神经内分泌肿瘤(在 66 个月时有 1 例肝转移)。在 25 例术前诊断可疑的患者中,有 9 例可能被认为治疗过度(即因良性非进行性无症状病变而行手术)。
中央胰腺切除术与良好的胰腺功能相关,但发病率高,死亡率高,这一数据高于文献报道。该手术最适用于年轻、健康的良性或低度病变患者,他们可以承受较高的术后发病率,并能从良好的长期结果中获益。